obesity drug news today glp-1 october 23 2025 Alarming rise in weight loss overdoses GLP-1 Weight-Loss Boom Linked To

Following the approval of exenatide to treat type 2 diabetes (USA: 2005

Steady dose escalation to higher doses than for glycaemic control are indicated if: BMI is 30 kg/m 2 , or BMI 27 to 30 kg/m 2 , and for the range 2730 kg/m 2 if there is one weight-related comorbidity (hypertension, dyslipidaemia, cardiovascular disease, obstructive sleep apnoea, prediabetes or T2D

9 GLP-1 synthesis is not exclusive to the endocrine system, as it can also originate from neurons within the CNS

Interplay of chronic kidney disease and the effects of tirzepatide in patients with heart failure, preserved ejection fraction, and obesity: the SUMMIT Trial

Immunocompromised patients, premature infants, critically ill individuals, those with central venous catheters, and patients with severe acute pancreatitis should avoid GLP-1 probiotics due to elevated risk of serious infections and adverse outcomes

Link injections to daily habits: Pair them with routines like brushing your teeth or a meal